1h Free Analyst Time
The publisher has been monitoring the irritable bowel syndrome market and it is poised to grow by $779.89 mn during 2021-2025, progressing at a CAGR of 10.09% during the forecast period. The report on the irritable bowel syndrome market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by unhealthy lifestyle habits and increasing incidence of gastrointestinal disorders.
The irritable bowel syndrome market analysis includes the type segment and geographic landscape.
The irritable bowel syndrome market is segmented as below:
By Type
- IBS-D
- IBS-C
- IBS-M
By Geographical Landscape
- North America
- Europe
- Asia
- ROW
This study identifies the increasing awareness of irritable bowel syndrome as one of the prime reasons driving the irritable bowel syndrome market growth during the next few years.
The report on irritable bowel syndrome market covers the following areas:
- Irritable bowel syndrome market sizing
- Irritable bowel syndrome market forecast
- Irritable bowel syndrome market industry analysis
The publisher's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading irritable bowel syndrome market vendors that include AbbVie Inc., Alfasigma Spa, Astellas Pharma Inc., AstraZeneca Plc, Bausch Health Companies Inc., Ironwood Pharmaceuticals Inc., Mallinckrodt Plc, Novartis AG, Sebela Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd. Also, the irritable bowel syndrome market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
Executive Summary- Market Overview
Market Landscape
- Market ecosystem
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2020
- Market outlook: Forecast for 2020 - 2025
Five Forces Analysis
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Type
- Market segments
- Comparison by Type
- IBS-D - Market size and forecast 2020-2025
- IBS-C - Market size and forecast 2020-2025
- IBS-M - Market size and forecast 2020-2025
- Market opportunity by Type
Market Segmentation by Drug type
- Market segments
- Comparison by Drug type
- Antibiotics - Market size and forecast 2020-2025
- Guanylate cyclase-C agonists - Market size and forecast 2020-2025
- Mu-opioid receptor agonists - Market size and forecast 2020-2025
- Chloride channel activators - Market size and forecast 2020-2025
- Others - Market size and forecast 2020-2025
- Market opportunity by Drug type
Customer landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2020-2025
- Europe - Market size and forecast 2020-2025
- Asia - Market size and forecast 2020-2025
- ROW - Market size and forecast 2020-2025
- Key leading countries
- Market opportunity By Geographical Landscape
- Market drivers
- Market challenges
- Market trends
Vendor Landscape
- Overview
- Landscape disruption
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- AbbVie Inc.
- Alfasigma Spa
- Astellas Pharma Inc.
- AstraZeneca Plc
- Bausch Health Companies Inc.
- Ironwood Pharmaceuticals Inc.
- Mallinckrodt Plc
- Novartis AG
- Sebela Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd.
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
List of Exhibits
- Key Finding 1
- Key Finding 2
- Key Finding 3
- Key Finding 5
- Key Finding 6
- Key Finding 7
- Key Finding 8
- Key Finding 9
- Parent market
- Market characteristics
- Offerings of vendors included in the market definition
- Market segments
- Global - Market size and forecast 2020 - 2025 ($ million)
- Global market: Year-over-year growth 2020 - 2025 (%)
- Five forces analysis 2020 & 2025
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition - Five forces 2020
- Type - Market share 2020-2025 (%)
- Comparison by Type
- IBS-D - Market size and forecast 2020-2025 ($ million)
- IBS-D - Year-over-year growth 2020-2025 (%)
- IBS-C - Market size and forecast 2020-2025 ($ million)
- IBS-C - Year-over-year growth 2020-2025 (%)
- IBS-M - Market size and forecast 2020-2025 ($ million)
- IBS-M - Year-over-year growth 2020-2025 (%)
- Market opportunity by Type
- Drug type - Market share 2020-2025 (%)
- Comparison by Drug type
- Antibiotics - Market size and forecast 2020-2025 ($ million)
- Antibiotics - Year-over-year growth 2020-2025 (%)
- Guanylate cyclase-C agonists - Market size and forecast 2020-2025 ($ million)
- Guanylate cyclase-C agonists - Year-over-year growth 2020-2025 (%)
- Mu-opioid receptor agonists - Market size and forecast 2020-2025 ($ million)
- Mu-opioid receptor agonists - Year-over-year growth 2020-2025 (%)
- Chloride channel activators - Market size and forecast 2020-2025 ($ million)
- Chloride channel activators - Year-over-year growth 2020-2025 (%)
- Others - Market size and forecast 2020-2025 ($ million)
- Others - Year-over-year growth 2020-2025 (%)
- Market opportunity by Drug type
- Customer landscape
- Market share By Geographical Landscape 2020-2025 (%)
- Geographic comparison
- North America - Market size and forecast 2020-2025 ($ million)
- North America - Year-over-year growth 2020-2025 (%)
- Europe - Market size and forecast 2020-2025 ($ million)
- Europe - Year-over-year growth 2020-2025 (%)
- Asia - Market size and forecast 2020-2025 ($ million)
- Asia - Year-over-year growth 2020-2025 (%)
- ROW - Market size and forecast 2020-2025 ($ million)
- ROW - Year-over-year growth 2020-2025 (%)
- Key leading countries
- Market opportunity By Geographical Landscape ($ million)
- Impact of drivers and challenges
- Vendor landscape
- Landscape disruption
- Industry risks
- Vendors covered
- Market positioning of vendors
- AbbVie Inc. - Overview
- AbbVie Inc. - Business segments
- AbbVie Inc. - Key offerings
- AbbVie Inc. - Key customers
- AbbVie Inc. - Segment focus
- Alfasigma Spa - Overview
- Alfasigma Spa - Product and service
- Alfasigma Spa - Key offerings
- Alfasigma Spa - Key customers
- Alfasigma Spa - Segment focus
- Astellas Pharma Inc. - Overview
- Astellas Pharma Inc. - Product and service
- Astellas Pharma Inc. - Key offerings
- Astellas Pharma Inc. - Key customers
- Astellas Pharma Inc. - Segment focus
- AstraZeneca Plc - Overview
- AstraZeneca Plc - Product and service
- AstraZeneca Plc - Key offerings
- AstraZeneca Plc - Key customers
- AstraZeneca Plc - Segment focus
- Bausch Health Companies Inc. - Overview
- Bausch Health Companies Inc. - Business segments
- Bausch Health Companies Inc. - Key offerings
- Bausch Health Companies Inc. - Key customers
- Bausch Health Companies Inc. - Segment focus
- Ironwood Pharmaceuticals Inc. - Overview
- Ironwood Pharmaceuticals Inc. - Business segments
- Ironwood Pharmaceuticals Inc. - Key offerings
- Ironwood Pharmaceuticals Inc. - Key customers
- Ironwood Pharmaceuticals Inc. - Segment focus
- Mallinckrodt Plc - Overview
- Mallinckrodt Plc - Business segments
- Mallinckrodt Plc - Key offerings
- Mallinckrodt Plc - Key customers
- Mallinckrodt Plc - Segment focus
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key offerings
- Novartis AG - Key customers
- Novartis AG - Segment focus
- Sebela Pharmaceuticals Inc. - Overview
- Sebela Pharmaceuticals Inc. - Product and service
- Sebela Pharmaceuticals Inc. - Key offerings
- Sebela Pharmaceuticals Inc. - Key customers
- Sebela Pharmaceuticals Inc. - Segment focus
- Teva Pharmaceutical Industries Ltd. - Overview
- Teva Pharmaceutical Industries Ltd. - Business segments
- Teva Pharmaceutical Industries Ltd. - Key offerings
- Teva Pharmaceutical Industries Ltd. - Key customers
- Teva Pharmaceutical Industries Ltd. - Segment focus
- Currency conversion rates for US$
- Research Methodology
- Validation techniques employed for market sizing
- Information sources
- List of abbreviations
Executive Summary
The publisher recognizes the following companies as the key players in the global irritable bowel syndrome market: AbbVie Inc., Alfasigma Spa, Astellas Pharma Inc., AstraZeneca Plc, Bausch Health Companies Inc., Ironwood Pharmaceuticals Inc., Mallinckrodt Plc, Novartis AG, Sebela Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd.Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is increasing awareness of irritable bowel syndrome.'
According to the report, one of the major drivers for this market is unhealthy lifestyle habits.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Alfasigma Spa
- Astellas Pharma Inc.
- AstraZeneca Plc
- Bausch Health Companies Inc.
- Ironwood Pharmaceuticals Inc.
- Mallinckrodt Plc
- Novartis AG
- Sebela Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd.
